Replies to post #516500 on Anavex Life Sciences Corp (AVXL)

[Hosai]

Well FDA rejected Donanenabs accelerated approval application based on their phase 2 because more data was needed. It clearly didn't mean Donanemab was worthless or doomed that the regulator refused to recommend approval.

https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-issues-complete-response-0